Lupus News

Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

Lack of antibody response following COVID-19 vaccination is the strongest predictor of breakthrough infection in patients with autoimmune rheumatic disease, according to data published in Annals of the Rheumatic Diseases.

Anifrolumab improves systemic lupus erythematosus disease activity across musculoskeletal, mucocutaneous and immunological domains, according to a post-hoc analysis of TULIP-1 and TULIP-2 data published in The Lancet Rheumatology.

The American Kidney Fund announced a new campaign called Looped in on Lupus Nephritis that is designed to improve diagnosis, awareness and equitable treatment of the disease among patients.

Older adults who took vitamin D with or without omega-3 fatty acid supplementation had a significantly lower rate of autoimmune disease over 5 years compared with those who took placebo, according to findings published in The BMJ.

African American women with systemic lupus erythematosus were found to be at increased risk for preterm and small-for-gestational age births, even prior to clinical diagnosis, according to data published in Arthritis Care & Research.

Current hydroxychloroquine use in patients with rheumatoid arthritis or systemic lupus erythematosus is associated with a reduced risk for cardiovascular events, including ischemic stroke and myocardial infarction, according to data.

One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.

Tenosynovitis detected through power Doppler ultrasound predicts rheumatoid and inflammatory arthritis development in patients with clinically suspect arthralgia, according to data published in Arthritis Research & Therapy.

Just 0.7% of fully vaccinated patients with inflammatory rheumatic and musculoskeletal disease experience a breakthrough COVID-19 infection, while only 4.4% demonstrate disease flare reactions, according to data.